Dr. Curran is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3130 Highland Ave
Cincinnati, OH 45219Phone+1 513-584-4268Fax+1 513-584-6955
Education & Training
- University of ChicagoFellowship, Hematology and Medical Oncology, 2012 - 2015
- University of ChicagoResidency, Internal Medicine, 2008 - 2011
- Stanford University School of MedicineClass of 2008
Certifications & Licensure
- OH State Medical License 2019 - 2025
- IL State Medical License 2011 - 2020
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study.Marlise R Luskin, Jun Yin, Gerard Lozanski, Emily Curran, Gregory Malnassy
Cancer. 2025-02-15 - 1 citationsImpact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leuke...Talha Badar, Ravi Narra, Alice S Mims, Michael G Heckman, Rory M Shallis
American Journal of Hematology. 2024-12-01 - 3 citationsBeat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.Fieke W Hoff, William G Blum, Ying Huang, Rina Li Welkie, Ronan T Swords
Blood Advances. 2024-10-22
Abstracts/Posters
- Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab OzogamicinEmily K Curran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with BlinatumomabEmily K Curran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
- Ponatinib and Blinatumomab Combination Safe and Effective in Patients with Newly Diagnosed, Ph-Positive ALLFebruary 3rd, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: